通脉饮对动脉粥样硬化临床前期病变(PCA)干预的探究.pdfVIP

提 要 目的：观察通脉饮治疗动脉粥样硬化临床前期（PCA）病变的临床疗效。方法： 将60例动脉粥样硬化临床前期病变患者随机分为两组，药物组30例，给予通脉饮治 疗；对照组 30 例，给予强化生活方式指导，随访 1 年时间。结果：药物组成员的总 胆固醇（TC）和低密度脂蛋白（LDL-C）有显著降低（P0.01）；对照组TC和LDL-C 有显著降低（P0.01），两组的甘油三脂（TG）和高密度脂蛋白（HDL-C）在治疗前 后没有达到统计学差异，药物组的TC较对照组降低（P=0.042，P0.05），LDL-C 也 显著降低（P=0.004，P0.01），而TG和HDL-C在两组间没有达到统计学差异。药物 组和对照组的颈动脉内-中膜厚度（IMT）和颈动脉粥样硬化斑块 Crouse 积分在治疗 后均有显著改善（P0.01），而在药物组和对照组间，则未达到统计学差异 （P=0.733,P=0.688）。药物组肱动脉-踝动脉脉搏波速度（baPWV）显著降低（P0.01）， 对照组则没有降低（P=0.156）；药物组baPWV低于对照组（P=0.037，P0.05）。结 论：通脉饮可以显著改善PCA患者的动脉结构和功能，强化生活方式也能一定程度的 改善动脉结构和功能，但效果弱于通脉饮。以祛痰化瘀法组方的通脉饮，治疗动脉粥 样硬化临床前期病变具有显著的疗效。 关键词 通脉饮；动脉粥样硬化临床前期病变；强化生活方式；临床研究 The Clinical Study on Preclinical Atherosclerosis(PCA)Treated with TheTONG-MAI-YIN Speciality:Internal medicine of TCM Author:Zhao Yanxiang Tutor:Wang Ying Abstract Objective:To observe the clinical effect of the prescription of TONG-MAI-YIN on Preclinical Atherosclerosis(PCA).Methods:60 patients of Preclinical Atherosclerosis were randomly divided into treatment group(30 cases) and control group(30 cases).TONG-MAI-YING capsule was given to treatment group. Strengthen way of life was given to control group.the influences of clinical effect on PCA were observed during 1 year.Results:In the treatment group and the control group ,the Total Cholesterol(TC) and LDL-C have been dramatically Reduced(P0.01). triglyceride(TG) and HDL-C have not reached statistical differences after they were treated .TC of the treatment group has been lower than the control group(P=0.042，P0.05) and also the LDL-C(P=0.004 ，P0.01).TG and HDL-C have not reached statistical differences between the two groups.IMT and Crouse integral have improved significantly after been treated in both groups(P0.01